Related Experiment Videos
Development of immunity to Epstein-Barr virus in Malaysian children
Insights
Epstein-Barr virus (EBV) seroconversion in Malaysian children shows primary infection by 4-6 months. Early life EBV infection may prevent infectious mononucleosis and inform vaccine strategies.
Area of Science:
- Virology
- Immunology
- Pediatrics
Background:
- Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus.
- Understanding EBV seroconversion patterns is crucial for public health, especially in populations with high rates of EBV-associated diseases like nasopharyngeal carcinoma.
- Malaysian children represent a unique demographic for studying early-life EBV infection.
Purpose of the Study:
- To determine the seroconversion pattern of Epstein-Barr virus (EBV) in Malaysian children.
- To investigate the timing of primary EBV infection and the role of maternal antibodies.
- To provide data for potential EBV vaccine development in Malaysia.
Main Methods:
- Longitudinal study of 98 Malaysian children aged 2 weeks to 12 years.
- Detection of maternal and infant antibodies including IgG, IgM, and IgA against EBV viral capsid antigen, nuclear antigen, and early antigen.
- Serological assays to quantify antibody titers.
Main Results:
- Maternal IgG antibodies to EBV viral capsid antigen were present in 70.6% of infants <3 months, decreasing to 26% by 7-9 months.
- Primary EBV infection, indicated by EBV-IgM, occurred between 4-6 months, with all children seropositive by 8 years.
- Maternal EBV nuclear antigen antibody titers declined by 4-12 months, with a resurgence in 40% of 12-year-olds.
Conclusions:
- Early-life EBV seroconversion in Malaysian children likely explains the low incidence of infectious mononucleosis.
- The observed seroconversion pattern suggests a potential window for administering an EBV subunit vaccine to infants aged 6-12 months.
- This research supports the development of EBV vaccines targeting EBV-associated diseases prevalent in Malaysia, such as nasopharyngeal carcinoma.
Abstract:
The pattern of seroconversion to Epstein-Barr virus (EBV) was determined in 98 Malaysian children aged 2 weeks to 12 years. Maternal IgG antibodies to EBV viral capsid antigen, ranging between 1:10 to 1:160 titer, were found in 70.6 percent of infants less than three months old, and dropped to 26 percent by seven to nine months. Primary infection, as denoted by emergence of EBV-IgM antibody, occurred at 4 to 6 months, and by eight years all children were seropositive. Maternal antibody titers to EBV nuclear antigen were detected in 52.9 percent of infants less than 3 months old, declined to undetectable levels by 4 to 12 months, and then increased to 40 percent by the age of 12 years. The IgA antibody to viral capsid antigen was absent in all but one infant aged one year; the child also had IgG anti-early antigen, The IgG antibody to EBV early antigen were present in 17.7 percent of the infants aged 3 months or less. This seroconversion to EBV in early life explains the absence of infectious mononucleosis in the Malaysian population. The data suggest that a subunit vaccine to protect against EBV-associated diseases, most notably nasopharyngeal carcinoma, commonly observed in Malaysians would have to be administered to infants 6-12 months of age.